NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Gregorc, Vanesa, Gaafar, Rabab M, Favaretto, Adolfo, Grossi, Francesco, Jassem, Jacek, Polychronis, Andreas, Bidoli, Paolo, Tiseo, Marcello, Shah, Riyaz, Taylor, Paul, Novello, Silvia, Muzio, Alberto, Bearz, Alessandra, Greillier, Laurent, Fontana, Floriana, Salini, Giulia, Lambiase, Antonio, O'Brien, Mary
Published in The lancet oncology (01.06.2018)
Published in The lancet oncology (01.06.2018)
Get full text
Journal Article
NGR‐hTNF and Doxorubicin as Second‐Line Treatment of Patients with Small Cell Lung Cancer
Gregorc, Vanesa, Cavina, Raffaele, Novello, Sivia, Grossi, Francesco, Lazzari, Chiara, Capelletto, Enrica, Genova, Carlo, Salini, Giulia, Lambiase, Antonio, Santoro, Armando
Published in The oncologist (Dayton, Ohio) (01.10.2018)
Published in The oncologist (Dayton, Ohio) (01.10.2018)
Get full text
Journal Article
Long-term survival outcomes of a placebo-controlled phase 3 trial with NGR-hTNF in combination with best investigator choice in relapsed malignant pleural mesothelioma (MPM)
Gregorc, Vanesa, Lazzari, Chiara, Bulotta, Alessandra, Viganò, Maria Grazia, Ghio, Domenico, Fontana, Floriana, Salini, Giulia, Lambiase, Antonio
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015
Gregorc, Vanesa, Viganò, Maria G, Bulotta, Alessandra, Citterio, Giovanni, Petrella, Giovanna, Brioschi, Elena, Ducceschi, Monika, Gianni, Luca, Colombi, Scialini, Rossoni, Gloria, Salini, Giulia, Redaelli, Emma, Lambiase, Antonio, Bordignon, Claudio
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM)
Gregorc, Vanesa, Bulotta, Alessandra, Viganò, Maria G, Citterio, Giovanni, Petrella, Giovanna, Brioschi, Elena, Ducceschi, Monika, Gianni, Luca, Colombi, Scialini, Rossoni, Gloria, Salini, Giulia, Savia, Veronica, Lambiase, Antonio, Bordignon, Claudio
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article